Literature DB >> 1597477

Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides.

B F Baker1, L Miraglia, C H Hagedorn.   

Abstract

The 5' cap structure of eucaryotic mRNA plays a pivotal role in mRNA metabolism. This report demonstrates that anti-sense oligonucleotides equipped with 3'-overhanging nucleotides modulate the amount of recombinant human eucaryotic initiation factor-4E that binds to a 5'-capped oligoribonucleotide. The degree of inhibition or enhancement of protein binding is dependent upon the number and sequence of overhanging nucleotides. A 45% inhibition of complexation was observed by the addition of one 3'-overhanging guanosine residue. Addition of a second residue (+2/GN) resulted in a higher degree of inhibition, 77-88%. In contrast, addition of one adenosine residue enhanced the formation of the eucaryotic initiation factor-4E-m7GpppRNA complex by 213%. Modulation of protein interactions with the 5'-cap structure is likely to effect several biological events, including pre-mRNA processing, transport of the mRNA from the nucleus to the cytoplasm and translation of the target mRNA. This targeting strategy in anti-sense chemistry may have practical applications in experimental biology and medicine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597477

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3' poly(A) end phenotype.

Authors:  Youkyung Hwang Choi; Curt H Hagedorn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

2.  RNA therapeutics: RNAi and antisense mechanisms and clinical applications.

Authors:  Jessica Chery
Journal:  Postdoc J       Date:  2016-07

3.  Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms.

Authors:  Timothy A Vickers; Stanley T Crooke
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 4.  Antisense oligonucleotide therapy for urologic tumors.

Authors:  Ingo Kausch; Andreas Böhle
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

5.  Characterization of the internal IRES element of the zebrafish connexin55.5 reveals functional implication of the polypyrimidine tract binding protein.

Authors:  Mahboob Ul-Hussain; Rolf Dermietzel; Georg Zoidl
Journal:  BMC Mol Biol       Date:  2008-10-23       Impact factor: 2.946

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.